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BACKGROUND Suboptimal platelet inhibition still represents an impor-
tant challenge, especially for patients undergoing percutaneous coronary
interventions (PCI). Chronic kidney disease (CKD) is a common comor-
bidity of patients with coronary artery disease, and may potentially inﬂu-
ence platelet reactivity. So far only few studies have assessed the role of
CKD on response to dual antiplatelet therapy with conﬂicting results.
Therefore, the aim of our study was to evaluate the impact of CKD on
platelet function in patients treated with dual antiplatelet therapy (DAPT)
after a recent acute coronary syndrome or PCI.
METHODS Patients treated with DAPT (ASA + clopidogrel or tica-
grelor) for an ACS or elective patients undergoing PCI were scheduled
for platelet function assessment at 30-90 days post-discharge. Platelet
function was assessed by whole blood impedance aggregometry
(Multiplate- Roche Diagnostics AG), HRPR was considered for ASPI
test >862 AU*min (for ASA) and ADP test values >417 AU*min (for
ADP-antagonists). Chronic renal failure was deﬁned as an estimated
glomerular ﬁltration rate of 60 ml/min/1.73m2 or less, calculated by
applying MDRD (Modiﬁcation of Diet in renal Disease) formula.
RESULTS Our population included a total of 537 patients of which 308
(57.3%) received ASA and clopidogrel and 229 (42.6%) received ASA
and ticagrelor. Patients with renal failure at baseline (101 out of 537,
18.8%) were older, with higher prevalence of history of hypertension,
myocardial infarction and coronary artery bypass graft surgery.
Moreover, they had a lower ejection fraction at baseline and were
more often in therapy with diuretics, but less often with statins at
admission. They had lower haemoglobin and higher glycated hae-
moglobin. HRPR was observed in 1.5% of patients treated with ASA
with no difference according to renal function (p ¼ 0.18). HRPR for
ADP-antagonists was observed in 23.7% of patients, with no difference
according to renal function (p ¼ 0.50). This result was conﬁrmed both
with clopidogrel (31.9% versus 38%, p ¼ 0.41) and ticagrelor (13.1%
versus 10.8%, p ¼ 0.99), also after correction for all baseline con-
founders (clopidogrel: adjusted OR [95%CI] ¼ 1.26 [0.60 - 2.63], p ¼
0.54) (ticagrelor: adjusted OR[95%CI] ¼ 0.95 [0.54 - 1.65], p ¼ 0.84).
The absence of association between renal function and platelet reac-
tivity was conﬁrmed at linear regression analysis both with clopi-
dogrel (r ¼ -0.04, p ¼ 0.52) and ticagrelor (r ¼ 0.006, p ¼ 0.92).
CONCLUSIONS In patients receiving dual antiplatelet therapy,
chronic renal failure did not inﬂuence ADP-mediated platelet reac-
tivity, with both ticagrelor or clopidogrel. No inﬂuence of chronic
renal failure was found on the effectiveness of ASA.
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BACKGROUND Platelet Inhibition and Patient Outcomes Trial (PLATO
trial) demonstrated that aspirin and ticagrelor were superior to aspirin
and clopidogrel in reducing thrombotic complications. Continuous
infusion of IIb/IIIa inhibitors (GPI) was used in 40% of patients with
ticagrelor in the PLATO trial. However, the inhibition of platelet ac-
tivity with ticagrelor starts rapidly and it is questionable whether
continuous infusion of GPI with ticagrelor is needed, We, therefore,
compared the impact of GPI bolus only vs. bolus and short infusion
of GPI with ticagrelor on percent inhibition of platelet aggregation
(%IPA) and outcome in patients with non-ST-segment myocardial
infarction (NSTEMI).METHODS A total of 70 patients with NSTEMI were randomized to
ticagrelor 190 mg loading and eptiﬁbatide bolus-only (TEP) vs. tica-
grelor loading and eptiﬁbatide bolus plus 2 h infusion(TEPI) admin-
istrated before stenting. Light transmission aggregometry was
performed and %IPA was calculated at baseline, 2 h, 6 h, and 24 h
using ADP, TRAP, collagen, and arachidonic acid (AA). Cardiac en-
zymes, hemoglobin and hematocrit were measured at baseline and 24
h. The event rates were determined at 30-day follow-up.
RESULTS In patients randomized to TEP vs. TEPI, there were no
signiﬁcant difference in the %IPA values at 2 h and 6 h with ADP 5mM
(100%  0.01 vs. 99%  0.25 and 99%  2.4 vs. 99%  1.2, respectively)
and with ADP 20 mM (Fig. 1), as well as with collagen. However, %IPA
was lower at 24 h (still >60) compared with that at 2 h and 6 h. Percent
IPA with TRAP 10 or 20 mM was higher at 6 h in patients randomized to
TEPI vs. TEP (87%  13 vs. 74%  17; P<0.01, respectively).This had no
bearing on outcomes since ADP was highly inhibited by ticagrelor at 6
h. There were no signiﬁcant differences in troponin or hemoglobin
levels among the groups. During follow-up, there was no stent
thrombosis or myocardial infarction.
CONCLUSIONS Percent IPA values with ADP and collagen were not
signiﬁcantly different comparing ticagrelor with eptiﬁbatide bolus
only vs. ticagrelor and eptiﬁbatide bolus plus 2 h infusion. Eptiﬁbatide
bolus only highly inhibited platelets aggregation while allowing
bridging to the antiplatelet effect of ticagrelor and circumventing the
need for continuous eptiﬁbatide infusion. There was no signiﬁcant
difference in bleeding or MI between the 2 groups.
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BACKGROUND Uninterrupted warfarin with intra-procedural heparin
is a commonly used anticoagulation strategy during atrial ﬁbrillation
